(PharmaNewsWire.Com, January 22, 2018 ) According to the report “ Europe Apheresis Market By Product (Devices And Disposables), Procedure (Donor, Therapeutic, Photopheresis), Application (Renal Diseases, Neurology, Cancer, Hematology, Autoimmune Diseases And Cardiovascular Diseases), Technology (Centrifuge And Membrane Separation), End User (Private Blood Collection Centres, Public Blood Collection Centres And Hospitals) - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2016–2021)” published by Market Data Forecast, the Europe Apheresis Market was worth USD 0.38 billion in 2016 and estimated to be growing at a CAGR of 8.74%, to reach USD 0.59 billion by 2021.
Apheresis is a medical procedure that involves removing whole blood from a donor or patient and separating the blood into individual components so that one particular component can be removed. The remaining blood components then are re-introduced back into the bloodstream of the patient or donor.
The industry is expected to have technology inventions aimed at delivering relatively more effective and faster results. Healthcare practitioners and researchers are now in the need for devices requiring minimum human intervention and introduction of fully automatic apheresis equipment with enhanced displays is expected to improve usage rates.
Increasing geriatric population base, escalating number of casualties leading to rising number of surgical procedures and growing public awareness regarding apheresis blood collection, rising prevalence of chronic diseases, growing blood platelet donors and increasing in R&D investments from biopharmaceutical companies will drive apheresis equipment market size. Growing demand for platelets and plasma due to rising incidence of blood related disorders, coupled with technological advancements should fuel apheresis equipment market growth. Risk of blood getting infected, lack of skilled personnel to carry out the procedure and unavailability of both donor & specific blood group are some of the factors hindering the growth of the market.
The Europe Apheresis Market is segmented into Product, Procedure, Application, Technology and End user. On the basis of product, the market is segmented into Apheresis devices and disposables. Based on procedure, the market is segmented into donor/automated apheresis and therapeutic apheresis. The Application segments include Renal Diseases, Neurology, Cancer, Hematology, Autoimmune Diseases and Cardiovascular Diseases. On the basis of technology, the market is segmented into Centrifuge and Membrane Separation. Centrifuge segment include Intermittent Flow and Continuous Flow. Based on End user, the market includes Private Blood Collection Centres, Public Blood Collection Centres and Hospitals.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. In Europe, Germany leads the Apheresis market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about Apheresis, financial strength to procure expensive tools, and favourable reimbursement policies. The Europe market has a share of 26% Global market and has a CAGR of 8.74% owing to presence of less stringent apheresis devices approval regulations and availability of large untapped opportunities in emerging European countries.
The key players in this market are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
